Treatment intensification in metastatic castration-sensitive prostate cancer: a real-world study in Alberta, Canada.

ABSTRACT:

Aim

To assess the current status of and factors associated with treatment intensification (TI) (with androgen receptor pathway inhibitors [ARPIs] and/or docetaxel) for metastatic castration-sensitive prostate cancer (mCSPC) in Canada.

Materials & methods

Retrospective analysis of data for 431 patients with mCSPC from the Alberta Prostate Cancer Research Initiative database (July 2014-March 2022). The primary objective was to assess the patient proportion receiving TI, time to TI, and associated factors. The secondary and exploratory objectives were evaluating TI patterns and factors associated with choice of therapy, respectively.

Results

Overall, 42% of patients received TI; most (65%) within 3 months post-index. TI was likely to occur within 3 months post-index in d

SUBMITTER: Yip SM 

PROVIDER: S-EPMC11988207 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature